论文部分内容阅读
目的:探讨丹参酮ⅡA磺酸钠联合二磷酸果糖对新生儿缺氧缺血性脑病患儿超敏C反应蛋白及脂联素水平的影响。方法:选取2010年10月-2012年10月收治的新生儿缺氧缺血性脑病患儿72例,随机将患儿分为丹参酮组,二磷酸果糖组及联合用药组,每组24例。另选同期收治的健康儿童30例作为对照组。比较分析缺养缺血患儿治疗前后超敏C反应蛋白和脂联素水平的变化情况,患儿心率和心电图恢复正常时间以及治疗过程中不良反应的发生情况。结果:与对照组新生儿相比,其他3组缺氧缺血性脑病患儿hs-CRP水平明显提高,而APN水平明显降低,差异均具有统计学意义(P<0.05)。与治疗前患儿相比,治疗后丹参酮组、二磷酸果糖组及联合用药组患儿hs-CRP水平明显降低,而仅联合用药组患儿APN水平明显提高,差异均具有统计学意义(P<0.05)。与联合用药组患儿相比,单用药丹参酮组和二磷酸果糖组患儿心率和心电图恢复正常的时间明显延长,差异均具有统计学意义(P<0.05)。3组患儿在治疗过程中均无明显的不良反应发生。结论:丹参酮ⅡA磺酸钠联合二磷酸果糖可作为新生儿缺氧缺血患儿合理的联合用药方案做进一步临床推广。
Objective: To investigate the effect of tanshinone Ⅱ A sulfonate combined with fructose diphosphate on the levels of high-sensitivity C-reactive protein and adiponectin in neonates with hypoxic-ischemic encephalopathy. Methods: Totally 72 children with neonatal hypoxic-ischemic encephalopathy were enrolled from October 2010 to October 2012. The children were randomly divided into tanshinone group, fructose diphosphate group and combination group, with 24 cases in each group. Another 30 cases of healthy children admitted to the same period as a control group. The changes of hypersensitive C-reactive protein and adiponectin in children with ischemia and ischemia were compared before and after treatment, the normal time of heart rate and electrocardiogram recovery, and the occurrence of adverse reactions during treatment. Results: Compared with the control group, the hs-CRP levels were significantly increased in the other 3 groups of neonates with hypoxic-ischemic encephalopathy, while the levels of APN were significantly decreased (P <0.05). Compared with the pretreatment children, the levels of hs-CRP in tanshinone group, fructose diphosphate group and combination group were significantly decreased after treatment, while the APN levels in the combination group were significantly increased (P <0.05). Compared with those in the combination group, the time to normalization of heart rate and electrocardiogram in children receiving tanshinone and fructose diphosphate alone were significantly longer, with significant differences (P <0.05). 3 groups of children in the course of treatment were no significant adverse reactions. Conclusion: Tanshinone Ⅱ A sulfonate combined with fructose diphosphate can be used as a reasonable combination regimen of neonatal hypoxic-ischemic children to do further clinical promotion.